Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities
Net (loss) income	$ (35,551,000)	$ 480,686,000
Gain from discontinued operations	0	539,538,000
Loss from continuing operations	(35,551,000)	(58,852,000)
Adjustments to reconcile net (loss) income to net cash used in operating activities
Non-cash interest expense		2,374,000
Loss on extinguishment of debt		25,011,000
Benefit from intra-period tax allocation		(30,239,000)
Depreciation and amortization expense	2,258,000	2,058,000
Non-cash activity related to discontinued operations		15,025,000
Loss (gain) on sale of property and equipment	184,000	(512,000)
Premiums paid on marketable securities	(40,000)
Amortization and accretion on marketable securities	(223,000)
Stock-based compensation expense	1,544,000	9,529,000
Loss on equity method investment	1,417,000
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(79,000)	(3,790,000)
Income taxes payable		8,141,000
Accounts payable, accrued expenses and other	(2,037,000)	2,494,000
Deferred rent	(1,055,000)	(209,000)
Net cash used in continuing operations for operating activities	(33,582,000)	(28,970,000)
Net cash used in discontinuing operations for operating activities		(46,416,000)
Net cash used in operating activities	(33,582,000)	(75,386,000)
Cash flows from investing activities
Purchase of property and equipment	(118,000)	(287,000)
Proceeds on sale of property and equipment		1,104,000
Proceeds from sale of business		575,000,000
Proceeds from maturities and sales of marketable securities	11,050,000
Purchases of marketable securities	(48,331,000)
Net cash (used in) provided by investing activities	(37,399,000)	575,817,000
Cash flows from financing activities
Payment of debt extinguishment costs		(20,124,000)
Proceeds from exercise of options to purchase common stock		6,079,000
Repayment of debt		(175,000,000)
Payment of dividend		(140,000,000)
Net cash used in financing activities		(326,446,000)
Net (decrease) increase in cash, cash equivalents and restricted cash	(70,981,000)	173,985,000
Cash, cash equivalents and restricted cash, beginning of period	94,217,000	22,300,000
Cash, cash equivalents and restricted cash, end of period	$ 23,236,000	196,285,000
Non-cash investing and financing activities
Purchases of property and equipment in accounts payable, accrued expenses and other		349,000
Receivables related to property and equipment sale in other current assets		155,000
Supplemental disclosure of cash flows
Cash paid for interest		28,872,000
Silver Creek Pharmaceuticals Inc [Member]
Cash flows from financing activities
Proceeds from issuance of Series C preferred stock by Silver Creek Pharmaceuticals, Inc., net of issuance costs		$ 2,599,000